VacV Biotech develops an oncolytic virus platform based on the vaccinia virus.
VacV Biotech has raised $3.0M in total funding. The most recent round was Seed. The last funding was announced in January 2022.
VacV Biotech's investors include Prox Ventures.
VacV Biotech is headquartered in London, United Kingdom.
VacV Biotech develops an oncolytic virus platform based on the vaccinia virus.
VacV Biotech is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VacV Biotech — Funding & Investors." VCBacked, January 1, 2022, https://www.vcbacked.co/company/vacv-biotech. Accessed October 3, 2026.
VCBacked. (2022). VacV Biotech — Funding & Investors. Retrieved October 3, 2026, from https://www.vcbacked.co/company/vacv-biotech
{{cite web |title=VacV Biotech — Funding & Investors |url=https://www.vcbacked.co/company/vacv-biotech |website=VCBacked |access-date=October 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated